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Summary The main recommendations for the use of ciclosporin in the management of psoriasis are: (i)
intermittent short courses (average of 12 weeks duration) of ciclosporin are preferable; (ii)
ciclosporin should be given in the dose range 2Æ5–5Æ0 mg kg)1 day)1 (doses greater than
5Æ0 mg kg)1 day)1 should only be given in exceptional circumstances); (iii) treatment regimens
should be tailored to the needs of each patient; (iv) selection of patients should take into account
psychosocial disability, as well as clinical extent of disease and failure of previous treatment; (v)
each patient’s renal function (as measured by serum creatinine) should be thoroughly assessed
before and during treatment; (vi) each patient’s blood pressure should be carefully monitored before
and during treatment; (vii) adherence to treatment guidelines substantially reduces the risk of
adverse events; (viii) long-term continuous ciclosporin therapy may be appropriate in a subgroup of
patients; however, duration of treatment should be kept below 2 years whenever possible; and (ix)
when long-term continuous ciclosporin therapy is necessary, annual evaluation of glomerular
filtration rate may be useful to accurately monitor renal function.
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Introduction
The efficacy of ciclosporin (Neoral) in the treatment
of severe plaque psoriasis is unquestionable, as dem-
onstrated by data from clinical trials.1 Dermatologists
accept this, although many clinicians continue to
have concerns regarding its use. These concerns
primarily relate to preconceptions surrounding side-
effects, such as renal impairment and hypertension,
and the lack of guidance regarding the appropriate
and effective use of ciclosporin in the treatment of
severe psoriasis.
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This report has been generated from the Ciclosporin in Psoriasis
Clinical Practice consensus conference held in Paris, France, on
5 September 2003. It involved experts in dermatology, clinical
pharmacology and nephrology. The purpose of the conference was to
develop a consensus statement on the clinical role of ciclosporin in
the treatment of psoriasis. This conference was supported by an
unrestricted educational grant from Novartis Pharma AG.
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An international conference was convened to
address these issues, by undertaking a multidisciplinary
expert review of the clinical data currently available on
ciclosporin therapy in psoriasis. The meeting endeav-
oured to provide a comprehensive revision of relevant
clinical practice since the previous consensus confer-
ence in 1996.2 The aims of the conference were: (i) to
examine the evidence for intermittent, short-course
ciclosporin therapy; (ii) to provide evidence-based
guidance on the effective use of ciclosporin therapy
for the treatment of psoriasis, and on the monitoring of
potential side-effects associated with its use; and (iii) to
present a unified methodology for the use of ciclosporin
in clinical dermatology practice.
The recommendations outlined in this document are
proposed only as a guide, and are intended for use in
conjunction with the physician’s clinical judgement.
Patient selection for ciclosporin therapy
in psoriasis
Patient selection for ciclosporin therapy should take into
account clinical extent of disease and ⁄ or psychosocial
disability, and ⁄ or response of severe disease to previous
treatment.
On clinical assessment, severe psoriasis is usually
defined as disease affecting more than 10–20% of the
skin, or as a Psoriasis Area Severity Index (PASI) > 10.
However, difficult to treat or severe psoriasis does not
necessarily equate with clinical extent of disease.3
Furthermore, the impact of psoriasis on a patient’s
quality of life (QoL) is often disproportionate to the
clinical severity of the condition. For example, one
patient with clinically minimal psoriasis may experi-
ence greater psychosocial disability than another with
far more extensive disease. Although there is some
relationship between severity of disease (as measured
by PASI) and QoL,4 self-reported severity (rather than
PASI) has been found to be the most significant
predictor of QoL.5
Ensuing loss of self-confidence and concerns over
physical appearance can impact on all areas of a
patient’s life, including personal relationships and
employment. Unfortunately, there is frequently a
mismatch in perception between patient and derma-
tologist regarding the impact of skin disease on QoL.6
Patients with psoriasis frequently feel highly stigma-
tized by their condition, which has a profoundly
negative effect on QoL.7
There is an important relationship between QoL
issues and treatment compliance. Patients with poor
QoL are less likely to adhere to their medication,8
particularly younger patients and those with clinically
severe disease.9 QoL may also have an impact on
treatment outcome, as psychological distress is known
to impair clearance of psoriasis in patients treated with
photochemotherapy.10
How then should severe disease be defined? Tradi-
tional methods have used physical sign-based assess-
ment, however, there has been a recent trend to
incorporate psychological evaluation, with particular
emphasis on QoL.3,11,12 The only remaining problem
with the integration of QoL scores into patient assess-
ment ⁄ intervention is that there is currently no defini-
tion on their practical meaning, in terms of clinical
decision-making.
Severe disease can also incorporate psoriasis that is
of limited extent but is physically disabling, such as on
the palms or soles, and disease that has been resistant
to other systemic therapies and ⁄ or when the patient is
unable to tolerate other systemic therapies.
In summary, when considering a patient for ciclosp-
orin therapy, an amended definition of disease severity
should be used that includes psychosocial disability, as
well as the clinical extent of disease and previous
response to treatment.
Clinical efficacy of ciclosporin in psoriasis
Ciclosporin is proven to rapidly induce remission of
psoriasis, significantly reduce the severity and extent of
disease, control disease symptoms, and improve quality
of life.
It is proven to be among the best therapeutic options
for the treatment of severe psoriasis, and a large
evidence base supports its use. Although an array of
medication is available for the therapy of severe
psoriasis, a significant number of patients remains
greatly dissatisfied with the efficacy of their treat-
ments.13 The limitations of current therapies impact on
treatment compliance and, ultimately, on clinical
outcome. Consequently, there is a genuine need for a
therapy that is effective in achieving disease control
and remission, enhances QoL, and is relatively safe and
well tolerated; ciclosporin is such a therapeutic agent.
Data from 18 randomised controlled trials (RCTs)
examining the efficacy and safety of ciclosporin in the
treatment of severe psoriasis are currently available.1
Of these, 13 RCTs investigated induction of remission
and five concerned maintenance therapy. These studies
used either short-course (average of 12 weeks) or long-
term ciclosporin therapy regimens.
1 2 C . E . M . G R I F F I T H S e t a l .
 2004 British Association of Dermatologists, British Journal of Dermatology, 150 (Suppl. 67), 11–23
The efficacy of intermittent short courses of ciclosp-
orin is confirmed by data from various studies.
Ciclosporin at doses of 2Æ5–5Æ0 mg kg)1 day)1 given
for 12–16 weeks rapidly produced marked improve-
ment or complete clearance of disease in 80–90% of
patients.14–19 Data from Faerber et al.19 demonstrate
the efficacy of ciclosporin in the dose range 2Æ5–
5Æ0 mg kg)1 day)1 (Fig. 1). The Psoriasis Intermittent
Short Course of Efficacy of Sandimmun Neoral (PISCES)
study involved 400 patients with severe psoriasis
who were given up to four courses of ciclosporin
(2Æ5–5Æ0 mg kg)1 day)1 for a maximum of
12 weeks).17 Results from PISCES demonstrated that
in some patients sustained remission could be achieved
after only one course of ciclosporin therapy in that 45%
of subjects had not relapsed 4 months after stopping
treatment and 31% had not relapsed after 6 months.
Significant improvements in QoL (91%), disease symp-
toms (98%), and PASI (91%) were also recorded with
intermittent short-course therapy.20
Longer-term, continuous ciclosporin therapy may be
required to maintain disease remission in a small
proportion of patients suffering from recalcitrant
psoriasis. Mean study doses of ciclosporin of
3Æ0–3Æ5 mg kg)1 day)1 were given for varying periods
of time, ranging from 621,22 through 1723 and up to
56 months.24 Significant clinical improvement was
observed in 8621 to 95%23 of patients, and the majority
(5821 to 91%22) was maintained on a ciclosporin dose
< 3Æ5 mg kg)1 day)1. During a long-term study in
which patients were treated for at least 12 months
with three doses of ciclosporin (1Æ25, 2Æ5 and
5Æ0 mg kg)1 day)1, respectively), 12Æ5% were main-
tained on the lowest dose (1Æ25 mg kg)1 day)1) with-
out loss of efficacy.25 From this it may be concluded
that ciclosporin doses < 2Æ5 mg kg)1 day)1 may be
sufficient to induce a remission in a subgroup of
patients, which makes individual dose-adjustment
mandatory. QoL scores also improved markedly follow-
ing 12 months of ciclosporin treatment, with patients’
perceptions of good health rising from 18% to 67% and
rates of psychiatric morbidity falling from 69% to
32%.26,27
In summary, data from RCTs have established
ciclosporin as an agent rapidly effective in achieving
control of psoriasis and inducing remission. Ciclosporin
also considerably improves patient QoL.
Management of renal side-effects
Renal side-effects associated with ciclosporin are
dose-related and occur almost exclusively during
prolonged exposure to ciclosporin and ⁄ or at doses
> 5Æ0 mg kg)1 day)1.28,29
Ciclosporin therapy causes increased vascular resist-
ance, which may result in reduced renal plasma flow
and decreased clearance of endogenous creatinine.
Subsequently this can manifest as an increase in serum
creatinine. Current treatment guidelines stipulate
reduction of ciclosporin dose if serum creatinine
increases by 30% above the baseline value (even if
this increase is within the normal range).30,31 How-
ever, any changes in renal performance are usually
functional and are normally quickly reversed by
cessation of ciclosporin therapy (if required).29
During continuous treatment with ciclosporin, the
proportion of patients experiencing an elevation in
serum creatinine above the baseline value increases
over time. Thus, only a minority of patients can be
maintained on ciclosporin for five continuous years or
more without experiencing changes in renal func-
tion.32,33 Study data have revealed that ciclosporin
nephropathy is intimately related to drug dose
Figure 1. Ciclosporin short-course therapy: response rate. Ciclospo-
rin 2.5–5.0 mg kg)1 day)1 is effective in a high proportion of pa-
tients, as shown by data from a meta-analysis of 510 patients with
severe plaque psoriasis treated with ciclosporin or placebo (total of
756 treatment cycles, maximum duration 12 weeks). *Proportion of
patients with ‡50% reduction in psoriasis area and PASI score over
the 12-week course of treatment. (NB: recommended starting dose of
ciclosporin is 2.5–5.0 mg)1kg day)1).19
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(i.e. > 5Æ0 mg kg)1 day)1) and duration of treat-
ment.28,29,34 The risk of renal toxicity from ciclosporin
during treatment of psoriasis is reduced by the use of
intermittent, short courses of the drug. Intermittent
therapy provides drug holidays to allow renal recovery
and restoration of normal renal function, thereby
returning serum creatinine concentration to baseline
levels.28 Renal safety during short-course ciclosporin
therapy is verified by the fact that only a minority of
patients (4%,19 17%16 and 10–27%17,18) experienced
an elevation in serum creatinine, which was typically
transient and commonly returned to baseline within
4 weeks following dose reduction or treatment cessa-
tion.17
The chance of developing renal impairment during
ciclosporin therapy can be minimized by screening
patients at the baseline assessment for any risk factors of
renal toxicity. These include pre-existing or new-onset
hypertension, advanced age, renal inflammatory con-
ditions, and abnormalities in absorption of ciclosporin.
In patients with psoriasis, concomitant medication, age,
weight, and the presence of hypertension are also
important risk factors for potential ciclosporin nephr-
opathy.31 Most importantly, the dose of ciclosporin used
should only exceed 5Æ0 mg kg)1 day)1 in exceptional
circumstances and the duration of treatment for each
patient should be only as long as is necessary to achieve
clearance (or near-clearance) of disease. Extended
periods of continuous ciclosporin use should be avoided
wherever possible, as changes in renal histology have
been reported after 3 years of such therapy.35
In summary, ciclosporin therapy is associated with a
risk of renal toxicity that is related to both dose of drug
and duration of treatment. As long as each patient is
properly screened, appropriately dosed, and monitored
regularly, risk can be controlled and corrected. Further
management guidelines for monitoring renal safety
during ciclosporin therapy in psoriasis can be found on
page 18 of this supplement.
Risk of malignancy during use of ciclosporin
in psoriasis
Non-melanoma skin cancer
Psoriasis patients treated with ciclosporin have a signifi-
cantly higher risk of non-melanoma skin cancer (NMSC)
compared with the non-psoriatic population (relative risk
6 : 1).36 However, this increased risk is observed exclu-
sively in patients who have been exposed previously to
psoralen-ultraviolet A (PUVA) therapy.36,37
The long-term use of immunosuppressants such as
ciclosporin is associated with a potential increase in the
risk of developing certain types of malignant tumour,
specifically cancers of the skin and lymphoid tis-
sue.38,39 A recent prospective cohort study investigated
the incidence of malignancy in patients with severe
psoriasis, who were on long-term therapy with ciclosp-
orin (n ¼ 1252; mean length of treatment 1Æ9 years;
mean dose 2Æ7–3Æ1 mg kg)1 day)1).36 Data showed
the overall incidence of malignancies in the study
cohort was twice that of the general population. This
was attributed to the six-fold higher incidence of skin
cancers, the majority of which were squamous cell
carcinomas (SCC).
However, the risk of malignancy, particularly of the
skin, is higher in people with psoriasis than in the
general population in any case,36,40–42 and exposure to
certain treatments for severe psoriasis are significant
risk factors for NMSC. For example, PUVA is associated
with a higher risk of NMSC, and this may be affected by
immunosuppressants (see below). Multivariate analysis
of the ciclosporin patient cohort in the study of Paul
et al.36 indicates that exposure to PUVA, methotrexate,
and other immunosuppressants are all significant risk
factors for NMSC (relative risks of 7Æ3, 4Æ6 and 3Æ5,
respectively). Patients with prolonged exposure to
ciclosporin (> 2 years cumulative treatment) had a
significantly increased risk of NMSC than those with
shorter exposures36 (Table 1).
PUVA is a tumour initiator that causes mutation in
various oncogenes (p53, H-ras).43,44 The risk of SCC
increases linearly with the number of PUVA sessions
received; the incidence of SCC is 14-fold greater for a
patient who has received more than 200 PUVA
treatments compared with one who has received
fewer than 100 treatments.43,45 This risk is even
larger for patients with skin phototypes I and II, or
with previous high exposure to tar ⁄ UVB. In the
ciclosporin cohort study, all patients who developed
Table 1. Standardized incidence ratio by malignancy and exposure
to ciclosporin36
SIR* 95% CI*
Any malignancy 2.1 1.6–2.9
Any skin malignancy 6.1 3.8–9.1
Non-melanoma skin malignancy 6.2 3.8–9.5
Malignant melanoma 4.7 0.6–17.0
Any non-skin malignancy 1.3 0.8–1.9
* Compared with normal population. SIR, standardized incidence
ratio; CI, confidence interval.
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SCC had received PUVA before the initiation of
ciclosporin.36
Suggested management guidelines include the fol-
lowing; (i) narrow-band UVB therapy, rather than
PUVA, should be the preferred first-line agent; (ii)
where PUVA is used, treatments should be limited to
fewer than 200 sessions (1000 J cm)2); (iii) the use of
immunosuppressant therapy in combination with UV
phototherapy is not recommended; (iv) during rota-
tional therapy, the use of ciclosporin should be avoided
immediately prior to and especially following photo
(chemo)therapy (PUVA); (v) exposure to immuno-
suppressants should be limited (intermittent short-
course therapy is preferred for ciclosporin) in patients
with a high cumulative exposure to PUVA; (vi) patients
with skin phototypes I and II should be closely
monitored; and (vii) patients with a previous history
of skin cancer should also be closely monitored, and the
use of immunosuppressants avoided in individuals who
have had melanoma or SCC. However, the use of
methotrexate, retinoids and fumarates before ⁄ after
ciclosporin therapy is permitted, and oral retinoids
may be beneficial in controlling PUVA ⁄ ciclosporin-
induced premalignant ⁄ malignant lesions.46
If one considers that a patient may require ciclosp-
orin treatment at some point in the future, it may be
appropriate to initiate treatment before PUVA in the
therapy cycle.
Non-skin malignancies
There is no significant increase in risk of non-skin
cancer with ciclosporin therapy compared with the
general population.36
Paul et al.36 found the incidence of non-skin cancer
in the psoriasis patient cohort was not significantly
different to that observed in the general population.
Prolonged exposure to ciclosporin (> 2 years cumula-
tive treatment) was not associated with a higher risk of
non-skin cancer. Multivariate analysis shows that
exposure to PUVA was the only significant risk factor
for non-skin malignancies (relative risk 2Æ5). However,
this cohort was too small to provide meaningful results
for individual types of non-skin cancers.
In summary, the treatment of psoriasis with ciclo-
sporin is associated with an increased incidence of
NMSC in those patients previously exposed to PUVA.
The risk of non-skin malignancies does not appear to be
increased in psoriasis patients treated with ciclosporin;
however, larger studies are needed to confirm these
findings.
Clinical considerations for ciclosporin therapy
in psoriasis
Patient management protocols have been established for the
use of ciclosporin in psoriasis, making drug initiation and
administration simple and straightforward.
A summary of points to consider during the use of
ciclosporin in the treatment of psoriasis and recom-
mendations for clinical practice can be found in
Table 2. The fundamental point is that therapy should
always be tailored to the needs of the individual
patient.
The efficacy of ciclosporin has been discussed above;
however, this agent also possesses several side-effects
that must be considered prior to the commencement of
therapy, the most important of these being renal
dysfunction and hypertension. Other side-effects
include gastrointestinal symptoms, hypertrichosis, gin-
gival hyperplasia, musculoskeletal symptoms (joint
pain, leg cramps), neurological symptoms (headache,
tremor, paraesthesia), fatigue and metabolic abnormal-
ities (hyperbilirubinaemia, hypercalcaemia, hypomag-
nesaemia, hyperuricaemia, hypertriglyceridaemia and
hypercholesterolaemia). If the presence of any of these
causes concern, the clinician should initiate dose
reduction and ⁄ or cessation of ciclosporin until the
side-effect diminishes. In the event of gingival hyper-
plasia, which is usually associated with poor oral
hygiene, the patient should consult a dentist.
The clinician should be aware of any drugs that have
the potential to either increase or decrease the systemic
exposure to ciclosporin when administered concomit-
antly.47 There are three main types of drug interaction:
(i) drugs that interfere with ciclosporin bioavailability
and ⁄ or metabolism (such as inducers or inhibitors of
cytochrome P450 iso-enzymes); (ii) drugs that have
potentially nephrotoxic effects; and (iii) drugs whose
metabolism may be affected by ciclosporin (Table 3).
Baseline blood pressure (BP) should be assessed
carefully to screen for hypertension (defined as
‡140 ⁄ 90 mmHg). Correct BP measurement technique
is vital and national hypertension society websites
should be consulted for guidance. Guidelines from the
World Health Organization,48 European Society of
Hypertension,49 and ⁄ or US Joint National Committee
on Hypertension50 should be used as reference for the
definition and management of arterial hypertension.
Blood pressure should be measured at 2-weekly inter-
vals for the first 2 months of ciclosporin therapy, and
monthly thereafter. If BP is noted to increase
beyond the upper limits of normal (i.e. systolic
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BP > 139 mmHg; diastolic BP > 89 mmHg), the
protocol outlined in Fig. 2 should be followed. Rising
BP should be controlled using clinically appropriate
methods, such as reduction in ciclosporin dose of
25–50% and ⁄ or the addition of an appropriate anti-
hypertensive agent. If dihydropyridine-type calcium
Table 2. Ciclosporin in psoriasis: clinical practice guidelines
Clinical category Details & recommendations
Patient selection; points to consider Patient’s perception of disease severity
QoL impairment
Psychiatric morbidity
Patient’s willingness to accept intermittent relapse following treatment cessation
Objective measurements of disease severity
Clinical extent of disease
Failure of previous treatment(s)
Efficacy & side effects of potential treatment
Indications for particular caution in use Malignancy ⁄ pre-malignant conditions: current or previous; excluding basal cell carcinoma
Immunodeficiency disorders: primary or secondary
Abnormal renal function
Severe hepatic dysfunction; hepatitis C
Hypertension* (controlled or uncontrolled): pre-existing or new onset
Severe infection: of any type
Unable or unwilling to undergo regular monitoring
Diabetes*
Obesity (dose ciclosporin at patient’s ideal body weight)
Aged >65 years*
Current ⁄ previous photo(chemo)therapy
Drug ⁄ alcohol abuse
(Note: Pregnancy is not known to be an absolute contra-indication to the use of ciclosporin)
Pre-treatment assessment Complete medical history & full physical ⁄ dermatological examination
Risk factors for renal toxicity
Renal inflammation, abnormal ciclosporin absorption, (see also * above)
Baseline renal function
Serum creatinine (taken after 12-hour fast, on at least 2 occasions)
Baseline blood pressure (taken using proper technique, on at least 2 occasions, should
be <140 ⁄ 90 mmHg)
Malignancy screening
Patients should be advised to follow national recommendations for cancer screening
(cervix, breast & prostate)
Other investigations
Liver function tests & serum K+ should be measured
Serum lipids, uric acid, bilirubin & Mg2+ are also commonly assessed
Starting dose & treatment regimen Dose
2.5–5.0 mg kg)1 day)1 (usually given as 2 divided doses)
Begin at the lower range & titrate according to clinical response
Regimen
Intermittent short-course therapy is preferred
Aim for disease clearance within 12 weeks
It is not necessary to taper off the dose at the end of treatment
Keep duration of treatment to a minimum
Treatment should be tailored to the needs of each patient
Monitoring during treatment Blood pressure
Measure at +2 weeks, +4 weeks & +6 weeks, then measure monthly thereafter
Renal function
Measure serum creatinine at 2-weekly intervals for the first 2 months, then measure monthly
thereafter
For patients on long-term therapy (>1 year continuous treatment) assess annual renal
function using creatinine clearance to measure GFR§
Serum lipids & Mg2+ should be measured 6 monthly
§ See also Fig. 4. GFR, glomerular filtration rate; K+, potassium; Mg2+, magnesium; QoL, quality of life.  See WHO guidelines,48 ESH
guidelines49 or JNC-VII50 for current definition of hypertension. See also National Hypertension Society websites for guidance on BP
recording, e.g. BHS website (UK) http://w3.abdn.ac.uk/BHS. More frequent readings will be necessary if values become abnormal.
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channel blockers are selected, nifedipine should not be
used due to the potential for a synergistic action with
ciclosporin in the development of gingival hyperplasia.
Data from RCTs have shown that only a minority of
patients (5–12%) developed new-onset hypertension
during short-course ciclosporin therapy, and the over-
whelming majority of these cases responded to dose
reduction and ⁄ or antihypertensive medication.17,19
Screening for renal toxicity caused by ciclosporin
therapy has been discussed above. Serum creatinine
should be measured, on at least two separate occasions,
following a 12-h fast. Patients should also be advised to
refrain from strenuous exercise immediately prior to
testing, as muscle metabolism can elevate serum
creatinine. Serum levels of creatinine should be meas-
ured at 2-weekly intervals for the first 2 months of
ciclosporin therapy, and monthly thereafter. If serum
creatinine is noted to increase by 30% or more of the
value at baseline (even if this figure remains within the
normal range), the protocol outlined in Fig. 3 should be
followed. Ciclosporin nephropathy usually responds
rapidly (< 4 weeks) to either reduction in dose or
cessation of ciclosporin treatment.17
It should be noted that a small number of patients
may have normal serum levels of creatinine but a
diminished glomerular filtration rate (GFR), which
indicates the presence of renal dysfunction. Measure-
ment of GFR is not routinely carried out in clinical
dermatology practice. However, creatinine clearance
can be easily calculated from the serum creatinine
value using the Cockcroft–Gault equation, which
provides a good estimate of GFR (Fig 4). As ciclosporin
nephropathy is closely related to duration of therapy,
GFR should be assessed annually in patients receiving
long-term continuous ciclosporin treatment.33
Patients should be advised to follow national recom-
mendations for cancer screening as appropriate (for
women, cervical smear, breast examination ⁄ imaging,
etc.; for men, prostate cancer screening). Recommen-
dations for the management of patients at risk of ⁄ with
a previous history of skin cancer are discussed above.
If a patient contracts an infection while receiving
ciclosporin therapy, the clinical response will depend
on the type of infectious agent and the severity of the
infection. For herpes virus infections, ciclosporin ther-
apy may be continued if the signs ⁄ symptoms are mild
and ⁄ or controlled by oral antivirals. For bacterial or
fungal infections, the patient should be treated
promptly with an appropriate antibiotic ⁄ antimycotic
agent (avoiding systemic macrolides and azoles, as
these drugs inhibit P450 iso-enzymes and elevate blood
ciclosporin levels). Clinicians should also be aware that
Table 3. Potential drug interactions with
ciclosporin therapy
Drug interaction Details
Drugs increasing CsA plasma levels
(mainly by inhibition of cytochrome
P450 system)
Calcium antagonists: diltiazem, nicardipine, verapamil





Others: oral contraceptives, allopurinol, danazole,
cholic acid
Drugs lowering CsA plasma levels






St John’s wort: Hypericum perforatum
Drugs increasing risk of nephrotoxicity Aminoglycosides: gentamycin, tobramycin




Others: H2 antagonists, trimethoprim
Drugs with increased plasma levels
when used concomitantly with CsA
Anti-gout agents: colchicine
NSAID* with strong first pass effect: diclofenac
Cardiac glycosides: digoxin
Corticosteroids: prednisolone
Note: clinicians should consult an up-to-date pharmaceutical reference whenever concomitant
medication is used during ciclosporin therapy
CsA, ciclosporin; NSAID, non-steroidal anti-inflammatory drug. * Salicylic acid can be used.
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vaccination may be less effective during ciclosporin
therapy, and the use of live attenuated vaccines should
be avoided.
There is still debate as to whether routine monitoring
of ciclosporin blood levels is necessary. In principle, two
methods of measurement are available. Trough-level
monitoring (C0) is common but does not necessarily
reflect ciclosporin exposure as a function of drug
intake. This is better assessed by measuring the
concentration of ciclosporin 2 h after drug intake
(C2).
51 Unlike in transplantation medicine, ciclosporin
trough blood levels do not properly predict renal
dysfunction and do not correlate with clinical
outcome.53 A recent literature review concluded that
trough-level monitoring was not recommended when
ciclosporin was used in doses < 3Æ0 mg kg)1 day)1
during short-term treatment. However, at higher doses,
C0 or C2 monitoring may be useful in certain patients in
order to detect ciclosporin levels above the recommen-
ded range.54
Prescribing guidelines for ciclosporin therapy
in psoriasis
Many patients with severe psoriasis can be managed
with intermittent short-course ciclosporin therapy.
Data from RCTs have shown that short courses of
ciclosporin in the range 2Æ5–5Æ0 mg kg)1 day)1 provide
optimum efficacy and safety for the induction of disease
remission in clinically severe patients. As most patients
do well on low doses of ciclosporin, 2Æ5 mg kg)1 day)1
is the recommended starting dose. This dose can be
increased by 0Æ5–1Æ0 mg kg)1 day)1 at intervals of 2–
4 weeks, according to clinical response. Treatment with
Figure 4. Calculation of glomerular filtration rate via serum creat-
inine. Creatinine clearance provides a good estimate of glomerular
filtration rate (GFR). Creatinine clearance can be calculated via the
Cockcroft-Gault equation using serum creatinine values, as shown
above.52 Alternatively, on-line GFR calculators such as http://
www.nephron.com/mdrd may be used.
Serum creatinine ↑ to ≥30% above baseline value
(even if within normal range)
Repeat measurement within 2 weeks
Creatinine rise sustained at ≥30% above baseline value
Reduce ciclosporin dose by ≥1 mg kg–1 day–1
(for minimum of 1 month)
Creatinine ↓ to <30% above baseline value
Continue ciclosporin treatment
Creatinine remains ≥30% above baseline value
Stop ciclosporin therapy
Creatinine returns to within 10% of baseline value
Ciclosporin treatment may be resumed
Figure 3. Renal toxicity during ciclosporin therapy: management.
Increased BP reading: 
≥90 mmHg DBP or ≥140 mmHg SBP
Repeat measurement within 2 weeks
Increased BP sustained
Reduce ciclosporin dose by 25–50%
Treat with hypotensive agent*
Use thiazide/thiazide-type diuretic
or CCB-DH† or ACEI or ARB
and/or
Figure 2. Rising blood pressure during ciclosporin therapy: man-
agement. *The major guidelines48-50 recommend that initial therapy
for uncomplicated hypertension should begin with a low-dose thiaz-
ide or thiazide-type diuretic, long-acting dihydropyridine-CCB, ACEI
or ARB. If there are any adverse effects with the initial choice of
agent, one of the other drug classes mentioned should then be sub-
stituted. Nifedipine should be avoided as it acts synergistically with
ciclosporin to cause gingival hyperplasia. ACEI, angiotensin con-
verting enzyme inhibitor; ARB, angiotensin II receptor blocker; BP,
blood pressure; CCB-DH, calcium channel blocker-dihydropyridine
type; DBP, diastolic BP; SBP, systolic BP.
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ciclosporin is given for an average of 12 weeks, during
which time the aim is for a substantial improvement in
disease that satisfies both physician and patient. The use
of adjunctive topical therapy is encouraged to reduce
ciclosporin dose requirements. Once remission has been
achieved, ciclosporin therapy is stopped and the patient
is monitored for signs of relapse. Upon relapse, ciclosp-
orin treatment should be recommenced at the previous
effective dose and titrated as required (to a maximum of
5Æ0 mg kg)1 day)1).
In situations where control of psoriasis needs to be
achieved swiftly, such as crisis intervention during acute
flares of disease, a so-called step-down dosing approach
may be more appropriate. Here, treatment begins at a
higher dose (still not exceeding 5Æ0 mg kg)1 day)1) and
is titrated down as symptoms abate.
Data from the PISCES study confirm the efficacy of
the short-course regimen; by day 84 of treatment,
approximately 80% of patients with severe psoriasis
had achieved at least 75% improvement in disease area
after the first treatment period17 (Fig. 5). Furthermore,
a considerable proportion of patients remained in
remission for up to 6 months after only one course of
treatment. The overwhelming majority of patients
(80%) needed only one or two courses of ciclosporin
treatment during the 1-year study period. The mean
dose requirement was 3Æ0–3Æ5 mg kg)1 day)1 for
treatment courses 1 and 2, and 3Æ5–4Æ0 mg kg)1 day)1
for courses 3 and 4.17 Median time to relapse was
109 days after course 1, falling to 52–77 days after
courses 2–4. Earlier relapse was found to correlate
with previous phototherapy and previous systemic
treatment, which may indicate a resistant ⁄ active form
of disease in some patients.17
PISCES safety data demonstrate that only 10% of
patients experienced elevated serum creatinine levels
(defined as ‡30% increase above baseline) during the
first treatment course, rising to 27% of patients during
the fourth course.17 Moreover, the ciclosporin-free
periods between treatments allowed renal function to
return to normal in affected patients. The safety of
short-course ciclosporin therapy was also proven with
regard to hypertension, as BP remained stable in
around 85% of PISCES patients.17 The minority that
developed new-onset hypertension responded well to
either dose reduction and ⁄ or cessation of ciclosporin.
A further advantage of short-course ciclosporin
therapy is the reduction in duration of exposure to
the drug, which consequently lowers the risk of side-
effects. For example, a PISCES extension study found
that patients received ciclosporin for only approxi-
mately 4 out of every 10 months when using this
regimen.18
In summary, ciclosporin short-course therapy, when
started at a dose of 2Æ5–5Æ0 mg kg)1 day)1, offers rapid
and significant resolution of extent and severity of
disease, sustained remission from psoriasis, positive
impact on QoL, reduction in overall exposure time
compared to continuous therapy, and has no signifi-
cant impact on renal function or hypertension when
therapeutic guidelines are met.
Longer-term use of ciclosporin as maintenance therapy
is indicated in a minority of patients with recalcitrant
disease.
A minority of patients has been identified in whom
continuous ciclosporin therapy is necessary to main-
tain disease remission.17,21,23 In these patients, the
minimum effective dose of ciclosporin required to
achieve substantial improvement in disease severity
should be used. This dose should be adjusted to
provide maximum clinical benefit and minimal drug
side-effects, and should not exceed 5Æ0 mg kg)1 day)1.
In the majority of studies, patients with
refractory disease were maintained on doses
< 3Æ5 mg kg)1 day)1.21–23 Continuous treatment dur-
ation should be limited to 2 years or less, wherever
possible. It is recommended that GFR be measured
annually in all patients receiving long-term therapy,
owing to the increased risk of ciclosporin-induced
nephropathy.
As with short-course treatment, longer-term use of
ciclosporin as maintenance therapy offers rapid
and sustained remission from disease, and long-term
acceptability to many patients.21–23 Side-effects are


















Figure 5. Cumulative rate of treatment success. Data from PISCES-1
study, during which 400 patients with severe psoriasis were treated
with short courses of ciclosporin (maximum 12 weeks duration,
maximum of four courses of therapy).17 *Remission is defined as 75%
improvement in psoriasis disease area.
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Combination and rotational therapy for psoriasis using
ciclosporin.
Several additional ciclosporin treatment regimens have
been published, which include combination and rota-
tional therapy concepts. A study by Clark et al.55
combined ciclosporin with low-dose methotrexate for
use in patients with recalcitrant disease. Rotational
therapy using mycophenolate mofetil with long-term
ciclosporin therapy was found to be reasonably suc-
cessful in a study by Davidson et al.56 Several other
agents have been added to rotational therapy cycles
with ciclosporin, including fumarates, sulphasalazine
and biologicals. The latter group may offer an alter-
native to maintenance treatment after induction of
remission by short-course ciclosporin. It has been
shown that alefacept, a fusion protein of lymphocyte
function-associated antigen-3 (LFA-3) and IgG1,
although being of lesser clinical efficacy than ciclo-
sporin, can induce a lasting remission in some patients
even after cessation of treatment.57 Furthermore,
efalizumab (an anti-CD11a humanized monoclonal
antibody), or etanercept (a tumour necrosis factor-
a-binding fusion protein) may be suitable for mainten-
ance therapy after initial ciclosporin intervention.58,59
However, long-term data about the safety of biologicals
in psoriasis are still lacking.
The impact on a psoriasis patient of inadvertently switching
between alternative formulations of ciclosporin is not fully
understood. To minimize any potential risk, it is important
that local guidelines are followed to ensure that the
appropriate brand is consistently dispensed to the patient.
Ciclosporin is a critical-dose drug, that is, a drug in
which a small change in dose or plasma concentration
may result in a clinically significant change in efficacy
and ⁄ or toxicity. Ciclosporin has formulation-dependent
bioavailability with a wide interindividual variability in
ciclosporin absorption, which explains why individual
dosing is required. The Neoral formulation of ciclo-
sporin offers a far greater consistency in drug delivery
than the original Sandimmun formulation. Recently,
generic manufacturers have marketed new formula-
tions of ciclosporin and it is realistic to expect that
additional generic formulations will be marketed in the
future. However, recommendations from several
national bodies state that the prescribing physician
should specify the exact brand to be dispensed. This is
because there are absorption differences among the
assorted formulations of ciclosporin related to pharma-
cokinetics, and there is also variation in the way each
patient reacts to a particular drug formulation.
Two important concepts are bioavailability and
bioequivalence. Bioavailability refers to the rate and
extent to which a drug is absorbed from a pharma-
ceutical formulation and delivered into the general
circulation. Two medicinal products are said to be
bioequivalent if their bioavailabilities (after adminis-
tration at the same dose) are similar to such a degree
that their effects (i.e. efficacy and safety) are presumed
to be essentially the same. Current regulations for
demonstrating bioequivalence require only a single
positive study, usually a single-dose comparison using
healthy male volunteers. The standard pharmacoki-
netic parameters are examined, and if the mean
bioavailability of the comparator drug lies within ±
20% of those from the innovator drug, the two drugs
are said to be bioequivalent. As there is no require-
ment to use patients with the target disease; to use
women, elderly people, or individuals from different
ethnic populations; to use different dose levels of the
drugs; or to examine food interactions, the intrinsic
limitations of these studies are evident.60–62 As these
studies only describe the response of a population,
they do not address what might happen in an
individual patient. Population bioequivalence is
adequate to determine if a particular product is of
sufficient quality to be prescribed, but gives no
indication of an individual’s likely reaction to that
formulation. For example, a patient who absorbs one
ciclosporin formulation satisfactorily will not neces-
sarily absorb another as well, thereby reducing effic-
acy. Alternatively, that individual may absorb a
greater amount, potentially leading to toxicity.
This concept is particularly important for clinicians,
who must consider all the possible effects of substitu-
ting one brand of ciclosporin for another, principally
those pertaining to patient safety and variation in
disease control. In line with national recommenda-
tions,63 prescribing by brand is recommended in order
to avoid potential adverse events of unplanned switch-
ing. Patients should also be educated about generic
drug substitution, so that they are aware if a different
formulation is unintentionally obtained.
Conclusions
The evidence base for ciclosporin therapy has proven it
to be a highly effective agent in the treatment of
psoriasis; which provides rapid and sustained disease
remission, and significantly improves patient QoL. The
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side-effect profile is well known and predictable, and
adherence to treatment guidelines extensively reduces
the risk of adverse events. The use of intermittent short-
course ciclosporin therapy has been established as the
optimum treatment regimen for most patients,
although long-term continuous therapy remains neces-
sary in a small subgroup with refractory disease.
The recommendations in this consensus statement
provide guidance for any clinician who is either
considering the use of, or continuing to use, ciclosporin
in the management of psoriasis.
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